AA
PGNX

ALPS Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

ALPS Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-172,337
Closed -$871K – 873
2019
Q3 		$871K Sell
172,337
-5,042
-3% -$25.1K 0.01% 330
2019
Q2 		$1.09M Sell
177,379
-26,824
-13% -$129K 0.01% 309
2019
Q1 		$948K Buy
204,203
+8,825
+5% +$39.9K 0.01% 339
2018
Q4 		$821K Buy
195,378
+46,996
+32% +$239K 0.01% 349
2018
Q3 		$930K Buy
148,382
+41,399
+39% +$318K 0.01% 425
2018
Q2 		$860K Buy
106,983
+12,735
+14% +$97.2K 0.01% 368
2018
Q1 		$703K Buy
94,248
+16,381
+21% +$109K 0.01% 376
2017
Q4 		$463K Buy
77,867
+8,663
+13% +$52.6K ﹤0.01% 623
2017
Q3 		$509K Buy
69,204
+5,817
+9% +$36.9K ﹤0.01% 478
2017
Q2 		$430K Buy
63,387
+3,122
+5% +$23K ﹤0.01% 644
2017
Q1 		$569K Sell
60,265
-7,054
-10% -$70.4K ﹤0.01% 306
2016
Q4 		$582K Buy
+67,319
New +$498K ﹤0.01% 290
2016
Q2 		– Sell
-78,505
Closed -$342K – 645
2016
Q1 		$342K Sell
78,505
-13,454
-15% -$59.9K ﹤0.01% 575
2015
Q4 		$564K Sell
91,959
-17,116
-16% -$112K 0.01% 306
2015
Q3 		$6.24K Buy
109,075
+39,953
+58% +$307K 0.01% 238
2015
Q2 		$516K Buy
69,122
+34,602
+100% +$209K ﹤0.01% 469
2015
Q1 		$206K Buy
+34,520
New +$217K ﹤0.01% 644

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ALPS Advisors's PGNX Position: Q4 2019 in Review

ALPS Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 172,337 shares — an estimated $871K sold.

ALPS Advisors first reported a position in PGNX in Q1 2015 and held it in 17 quarters. The position peaked at $1.09M in Q2 2019. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • ALPS Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • ALPS Advisors sold 172,337 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $871K.
  • ALPS Advisors first reported a position in Progenics Pharmaceuticals Inc in Q1 2015 and held it in 17 quarters.
  • ALPS Advisors's Progenics Pharmaceuticals Inc position peaked at $1.09M in Q2 2019.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on ALPS Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.